SLE in 2011: Deciphering the role of NETs and networks in SLE

Nature Reviews Rheumatology

Volumn 8, Issue 2, 2012, Pages 68-70

  Dörner, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BELIMUMAB; PLACEBO; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADAPTIVE IMMUNITY; B LYMPHOCYTE ACTIVATION; CELLULAR PARAMETERS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INNATE IMMUNITY; NEUTROPHIL EXTRACELLULAR TRAP; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; EXTRACELLULAR SPACE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; NEUTROPHILS; PHAGOCYTOSIS;

EID: 84856608202     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.200     Document Type: Review

References (10)

1. Craft, J. Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci. Transl. Med. 3, 73ps9 (2011).
2. + B-cell population is important for the development of autoimmunity. Blood 118, 1305-1315 (2011).
3. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002). (Pubitemid 34406754)
4. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004). (Pubitemid 38314426)
5. Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011).
6. Dörner, T., Giesecke, C. & Lipsky, P. E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 13, 243 (2011).
7. Taylor, K. E. et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genetics 7, e1001311 (2011).
8. Lindh, E. et al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc. Natl Acad. Sci. USA 105, 18466-18471 (2008).
9. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
10. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).